ERDAFITINIB FOR INTRAVESICAL ADMINISTRATION FOR USE IN THE TREATMENT OF BLADDER CANCER

Provided herein are methods of treatment, erdafitinib for use and use of erdafitinib for the treatment of bladder cancer harboring one or more FGFR alterations comprising locally delivering erdafitinib into the bladder of a patient. L'invention concerne des méthodes de traitement, l'erdafi...

Full description

Saved in:
Bibliographic Details
Main Authors GIESING, Dennis, DANIEL, Karen, BEEHARRY, Neil, HEYNS, Philip Erna H, TIAN, Shaozhou Ken, KIMPE, Kristof Leonard, MAMIDI, Srinivas, SMIRNOV, Denis A, PATEL, Jaymala, RAJPUROHIT, Yashoda Rani, DUBOIS, Kristof Johan W, DHONDT, Jens Julien Maurits Andre
Format Patent
LanguageEnglish
French
Published 22.08.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Provided herein are methods of treatment, erdafitinib for use and use of erdafitinib for the treatment of bladder cancer harboring one or more FGFR alterations comprising locally delivering erdafitinib into the bladder of a patient. L'invention concerne des méthodes de traitement, l'erdafitinib destiné à être utilisé pour le traitement d'un cancer de la vessie hébergeant une ou plusieurs altérations du FGFR, ainsi que l'utilisation d'erdafitinib pour un tel traitement, comprenant l'administration locale d'erdafitinib dans la vessie d'un patient.
Bibliography:Application Number: WO2024US16031